Loading...

PerCP/Cyanine5.5 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_PerCPCyanine55_CD8a_Antibody_102318
C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).
  • 53-6dot7_PerCPCyanine55_CD8a_Antibody_102318
    C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Save
100733 25 µg ¥15,490
100734 100 µg ¥42,190
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/mL
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is < 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  2. Yoon J et al. 2018. J Vis Exp. -141 . PubMed
  3. Turecamo SE, et al. 2018. Matrix Biol. 67:01:00. PubMed
  4. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  5. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  6. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  7. Lang J, et al. 2020. Nat Commun. 11:1338. PubMed
  8. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  9. Ferapontov A, et al. 2023. Nat Commun. 14:976. PubMed
  10. Shi X, et al. 2023. iScience. 26:106143. PubMed
  11. Pattnaik A, et al. 2023. Vaccines (Basel). 11:. PubMed
  12. Abdelwahab T, et al. 2023. iScience. 26:106698. PubMed
  13. Milighetti M, et al. 2023. iScience. 26:106937. PubMed
  14. Hu Y, et al. 2023. JCI Insight. 8:. PubMed
  15. Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed
  16. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  17. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  18. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  19. Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed
  20. Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed
  21. Stone ET, et al. 2022. Cell Rep. 38:110388. PubMed
  22. Goncharov NV, et al. 2022. J Evol Biochem Physiol. 58:230. PubMed
  23. Wemlinger SM, et al. 2022. J Immunol. 208:1566. PubMed
  24. Parga-Vidal L, et al. 2022. Eur J Immunol. 52:1095. PubMed
  25. Wang S, et al. 2022. Sci Adv. 8:eabn3883. PubMed
  26. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  27. Silva Pereira S, et al. 2022. Elife. 11: . PubMed
  28. Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed
  29. Balood M, et al. 2022. Nature. 611:405. PubMed
  30. Ge Y, et al. 2022. iScience. 25:105437. PubMed
  31. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  32. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  33. Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed
  34. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  35. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  36. Ai L, et al. 2023. Cell Discov. 9:9. PubMed
  37. Chen L, et al. 2023. Bioeng Transl Med. 8:e10377. PubMed
  38. Teymournejad O, et al. 2023. NPJ Vaccines. 8:3. PubMed
  39. Marritt KL, et al. 2023. Front Immunol. 13:1087991. PubMed
  40. Wang R, et al. 2023. iScience. 26:105954. PubMed
  41. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  42. Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed
  43. Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed
  44. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  45. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  46. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  47. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  48. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  49. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
  50. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  51. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  52. Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
  53. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  54. Cornax I, et al. 2021. Microorganisms. 9:00. PubMed
  55. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  56. Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed
  57. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  58. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
  59. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  60. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  61. Sawada J, et al. 2021. Am J Pathol. 191:396. PubMed
  62. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  63. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  64. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  65. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  66. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  67. Pack AD, et al. 2021. Cell Reports. 36:109586. PubMed
  68. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  69. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
  70. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  71. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  72. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  73. Juul-Madsen K, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  74. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  75. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  76. Hong JY, et al. 2020. Cell. 180(5):847-861. PubMed
  77. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  78. Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed
  79. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  80. Solanki A, et al. 2018. Development. 145. PubMed
  81. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  82. Green DP, et al. 2019. Neuron. 101:412. PubMed
  83. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  84. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  85. Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed
  86. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  87. Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed
  88. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  89. Smith AS, et al. 2022. J Immunother Cancer. 10:. PubMed
  90. Agrawal M, et al. 2021. Cells. 10:. PubMed
  91. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  92. Chen D, et al. 2020. Cancer Immunol Res. 8:883. PubMed
  93. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  94. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  95. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  96. Dekhtiarenko I, et al. 2013. J Immunol. 190:3399. PubMed
  97. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  98. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed
  99. Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed
  100. Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed
  101. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  102. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  103. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  104. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  105. Novince CM, et al. 2017. Sci Rep. 7:5747. PubMed
  106. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  107. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  108. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  109. Tondini E, et al. 2022. NPJ Vaccines. 7:64. PubMed
  110. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  111. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  112. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  113. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  114. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  115. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  116. Pilzecker B, et al. 2016. Nucleic Acids Res. 44: 4734 - 4744. PubMed
  117. Chung L et al. 2018. Cell host & microbe. 23(2):203-214 . PubMed
  118. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  119. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  120. Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed
  121. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  122. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  123. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  124. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  125. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  126. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  127. White C, et al. 2015. J Immunol. 194:697. PubMed
  128. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  129. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  130. Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed
  131. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  132. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  133. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  134. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  135. Zhao D, et al. 2020. Cancer Discov. 10:1374. PubMed
  136. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
  137. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  138. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  139. Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed
  140. Shi R, et al. 2019. J Cancer. 10:367. PubMed
  141. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  142. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  143. Wuggenig P, et al. 2020. Commun Biol. 3:130. PubMed
  144. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  145. Wüthrich M, et al. 2021. MBio. 12:e0201821. PubMed
  146. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  147. Kohn EM, et al. 2022. J Immunol. 208:1417. PubMed
  148. Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed
  149. Tang Y, et al. 2019. Nat Commun. 10:4157. PubMed
  150. Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed
  151. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  152. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  153. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  154. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  155. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  156. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  157. Highton AJ, et al. 2019. Wellcome Open Res. 4:78. PubMed
  158. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  159. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  160. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  161. Mezzapelle R, et al. 2021. EMBO Mol Med. 13:e12344. PubMed
  162. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  163. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  164. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  165. Woodring T, et al. 2022. iScience. 25:104934. PubMed
  166. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  167. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  168. Younes AI, et al. 2021. Transl Oncol. 14:100983. PubMed
  169. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  170. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  171. Bennion BG, et al. 2019. J Virol. 93. PubMed
  172. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  173. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  174. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  175. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  176. Okada R, et al. 2021. EBioMedicine. 67:103345. PubMed
  177. MaruYama T, et al. 2015. J Leukoc Biol. 98: 385-393. PubMed
  178. Borkner L, et al. 2017. J Immunol. 10.4049/jimmunol.1602115. PubMed
  179. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  180. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  181. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  182. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  183. Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed
  184. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  185. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  186. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  187. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  188. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  189. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  190. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  191. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  192. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  193. Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
  194. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  195. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  196. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  197. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  198. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  199. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  200. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  201. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  202. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  203. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  204. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  205. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  206. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  207. Li A, et al. 2018. Cancer Lett. 431:54. PubMed
  208. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  209. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  210. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  211. Gorman M, et al. 2016. J Virol. 90: 8212 - 8225. PubMed
  212. Goc J, et al. 2021. Cell. 184:5015. PubMed
  213. Strattan E, et al. 2020. Frontiers in Immunology. 2.131944444. PubMed
  214. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  215. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
  216. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  217. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  218. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  219. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  220. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  221. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  222. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  223. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
RRID
AB_2075239 (BioLegend Cat. No. 100733)
AB_2075238 (BioLegend Cat. No. 100734)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 10/23/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account